On January 2, 2024, Prof. Li Tang and Dr. Yugang Guo, co-founders of Leman Biotech, published a paper in the top international academic journal Nature Biotechnology (IF=68), titled "IL-10-expressing CAR-T cells resist dysfunction and mediate durable clearance of solid tumors and metastases". The paper comprehensively reveals the preclinical research results of metabolically enhanced Meta 10 CAR-T therapy for solid tumors. The relevant findings suggest that Meta 10 CAR-T has enormous potential for curing solid tumors.

Leman Biotech was invited to participate in the Swiss Group for Clinical Cancer Research (SAKK)'s Cellular Therapies Workshop held as part of the 6th annual Swiss Oncology and Hematology Congress.Leman Biotech was one of four Top Swiss companies invited to present in the sessions: "Engineered Cells" and "Manufacturing Devices & Technology," showcasing their cutting-edge technologies and advancements in cell therapy development. Prof. Dr. George Coukos had previously given a welcome note and opened the session.

Recently, the "15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference," also known as the Qisihui Conference, was held in Hangzhou. During the conference, the "Top 100 Best in China Pharmaceutical Innovation Value Discovery" for the year 2022-2023 was announced. Leman Biotech was successfully selected for its project "AI Empowered Metabolically Enhanced Immunotherapy."

On October 22nd, the National Cancer Centre Singapore (NCCS) hosted a Charity GALA Dinner with the theme "Celebrating the past, Building hope for the future." Leman Biotech, as a representative of emerging enterprises in cancer immunotherapy, was invited by NCCS. Dr. Dudu Tong, the R&D Director, attended the grand event on behalf of the company and received a cordial reception from prominent figures, including Mr. Heng Swee Keat, the Deputy Prime Minister of Singapore.

On October 12-13, the BioCon Asia 2023-Advanced Cell & Gene Therapy (ACGT) Conference was held in Singapore. Dr. Dudu Tong, the R&D Director of Leman Biotech, participated in the conference and delivered a presentation titled "Metabolically armed CAR-T cells for treatment of solid tumors."

Leman Biotech Makes Multiple Breakthroughs in IIT Clinical Trial for hematological malignancies: 10 Consecutive Patients Achieve Complete Remission, CAR-T Treatment Dose as Low as 1% of the conventional cell therapies, First Central Nervous Metastasis Patient Achieves Sustained Complete Remission for Over 6 Months.

On September 8-9, 2023, the 7th Immunogene and Cell Therapy Conference (IGC 2023) was held at the Beijing International Convention Center. Dr. Youjia Li, R&D Director of Leman Biotech, was invited to deliver a keynote speech. She shared the latest clinical research progress on metabolically enhanced CAR-T cell therapy, receiving high attention from the participating experts.